Literature DB >> 29128067

Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis.

Xueyan Chen1, Sindhu Cherian2.   

Abstract

Flow cytometry plays an indispensible role in the diagnosis and subclassification of acute myeloid leukemia (AML). Using a multiparametric approach, flow cytometry immunophenotyping has the advantage of efficiency with high sensitivity. This article reviews the general gating strategy, antibody panels for routine analysis, and additional markers for lineage assignment in the subclassification of AML. Also discussed are diagnostic immunophenotypic features of hard-to-classify entities considered within the differential diagnosis of AML. Finally, briefly presented are the principles underlying the use of flow cytometry for minimal residual disease detection.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Flow cytometry; Minimal residual disease; Mixed phenotype acute leukemia

Mesh：

Year:  2017        PMID： 29128067     DOI： 10.1016/j.cll.2017.07.003

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN： 0272-2712            Impact factor:   1.935


  8 in total

1.  Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia.

Authors:  Wingchi K Leung; Aster Workineh; Shivani Mukhi; Ifigeneia Tzannou; Daniel Brenner; Norihiro Watanabe; Ann M Leen; Premal Lulla
Journal:  Blood Adv       Date:  2020-01-28

Review 2.  Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects.

Authors:  Jan-Niklas Eckardt; Martin Bornhäuser; Karsten Wendt; Jan Moritz Middeke
Journal:  Blood Adv       Date:  2020-12-08

Review 3.  "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?

Authors:  Xueyan Chen; Jonathan R Fromm; Kikkeri N Naresh
Journal:  Leukemia       Date:  2022-01-19       Impact factor: 11.528

Review 4.  Aberrant Phenotypes in Acute Myeloid Leukemia and Its Relationship with Prognosis and Survival: A Systematic Review and Meta-Analysis.

Authors:  Lucio Henrique Sousa Pinheiro; Louise Dantas Trindade; Fernandes de Oliveira Costa; Nathanielly de Lima Silva; Alex Freire Sandes; Marco Antônio Prado Nunes; Cristiane Bani Correa; Carlos Arthur Cardoso Almeida; Geydson Silveira da Cruz; Divaldo Pereira de Lyra Junior; Dulce Marta Schimieguel
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-10-01

5.  High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia.

Authors:  Chengliang Yin; Junyan Zhang; Wei Guan; Liping Dou; Yuchen Liu; Ming Shen; Xiaodong Jia; Lu Xu; Rilige Wu; Yan Li
Journal:  Front Oncol       Date:  2021-03-02       Impact factor: 6.244

Review 6.  Put in a "Ca2+ll" to Acute Myeloid Leukemia.

Authors:  Clara Lewuillon; Marie-Océane Laguillaumie; Bruno Quesnel; Thierry Idziorek; Yasmine Touil; Loïc Lemonnier
Journal:  Cells       Date:  2022-02-04       Impact factor: 6.600

7.  NADH dehydrogenase subunit 1/4/5 promotes survival of acute myeloid leukemia by mediating specific oxidative phosphorylation.

Authors:  Ye Kuang; Chuanmei Peng; Yulin Dong; Jia Wang; Fanbin Kong; Xiaoqing Yang; Yang Wang; Hui Gao
Journal:  Mol Med Rep       Date:  2022-04-15       Impact factor: 3.423

8.  Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML.

Authors:  Jiaxiong Tan; Zhi Yu; Jingying Huang; Youchun Chen; Shuxin Huang; Danlin Yao; Ling Xu; Yuhong Lu; Shaohua Chen; Yangqiu Li
Journal:  Biomark Res       Date:  2020-02-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.